PT - JOURNAL ARTICLE AU - Crichton, Megan L. AU - Lonergan, Mike AU - Barker, Alan F. AU - Sibila, Oriol AU - Goeminne, Pieter AU - Shoemark, Amelia AU - Chalmers, James D. TI -吸入氨曲南可改善支气管扩张患者的咳嗽和痰液产生症状:a 后hoc分析AIR-BX研究AID - 10.1183/13993003.00608-2020 DP -2020年7月01 TA -欧洲呼吸杂志PG - 2000608 VI - 56 IP - 1 4099 - //www.qdcxjkg.com/content/56/1/2000608.short 4100 - //www.qdcxjkg.com/content/56/1/2000608.full SO - Eur Respir J2020 01年7月;吸入抗生素可改善症状评分，但尚不清楚治疗后哪些特定症状会改善。对问卷数据的项目级分析可以让我们确定哪些特定症状对治疗的反应最好。方法对AIR-BX1研究和吸入氨曲南与安慰剂治疗支气管扩张的两项试验进行事后分析。从生活质量支气管扩张(QOL-B)呼吸症状量表中提取个体项目，代表9种不同症状的严重程度。使用广义线性模型来评估从基线到第一个治疗周期结束，治疗与安慰剂的症状变化，并使用混合模型来评估整个16周试验的变化。结果氨曲南改善咳嗽(差异0.22,95% CI 0.08 ~ 0.37;p=0.002)，痰量(0.30,95% CI 0.15-0.44;p<0.0001)和痰色(0.29,95% CI 0.15-0.43;P<0.0001)与安慰剂相比，相当于咳嗽改善了20%，痰液产量和颜色改善了25%。 Similar results were observed for cough, sputum production and sputum purulence across the trial duration (all p<0.05). Patients with higher sputum production and sputum colour scores had a greater response on the overall QOL-B (difference 4.82, 95% CI 1.12–8.53; p=0.011 for sputum production and 5.02, 95% CI 1.19–8.86; p=0.01 for sputum colour). In contrast, treating patients who had lower levels of bronchitic symptoms resulted in shorter time to next exacerbation (hazard ratio 1.83, 95% CI 1.02–3.28; p=0.042).Conclusion Baseline bronchitic symptoms predict response to inhaled aztreonam in bronchiectasis. More sensitive tools to measure bronchitic symptoms may be useful to better identify inhaled antibiotic responders and to evaluate patient response to treatment.Inhaled aztreonam improves cough and sputum production in patients with bronchiectasis but has no impact on other symptoms. More sensitive tools to measure bronchitic symptoms may be useful to enrich for responders and to evaluate patient benefit. https://bit.ly/2UMKM5i